Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 1:04 AM
Ignite Modification Date:
2025-12-25 @ 1:04 AM
NCT ID:
NCT07015593
Eligibility Criteria:
Inclusion Criteria:
* Age 18 or older
* Newly diagnosed stage III or IV CC or EC
* Completed their initial conventional therapies which must include at least chemotherapy, radiotherapy or a combination between Dec. 2022 to Dec. 2024 and the therapies were within 6 months after diagnosis.
* Told by their physician that their disease is stable.
* Patients must have informed consent form (ICF) signed for the study.
Exclusion Criteria:
* Previously treated with targeted biologic therapy anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor.
* Previously participated in or participating in a clinical trial.
* Patients who received another line of therapy after initial therapy.
* Unable or unwilling to provide informed consent.
* Not fluent in local language.
* Indicates or exhibits hearing difficulties, which would make a conversation challenging.
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
18 Years
Study:
NCT07015593
Study Brief:
Protocol Section:
NCT07015593